Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,301-1,350 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__86_B8,9 | Lung | Primary cancer | 2,955 | Tumor/Malignant | 43.8% | 0.87 | 0.35 |
| NSCLC_38242124__IMC__86_C1,1 | Lung | Primary cancer | 1,909 | Tumor/Malignant | 56.7% | 0.98 | 0.05 |
| NSCLC_38242124__IMC__86_C1,11 | Lung | Primary cancer | 2,827 | Tumor/Malignant | 44.5% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__86_C1,12 | Lung | Primary cancer | 3,405 | Tumor/Malignant | 35.4% | 0.46 | 0.84 |
| NSCLC_38242124__IMC__86_C1,3 | Lung | Primary cancer | 3,623 | Tumor/Malignant | 64.1% | 1.00 | 0.03 |
| NSCLC_38242124__IMC__86_C1,4 | Lung | Primary cancer | 3,712 | Tumor/Malignant | 91.3% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_C2,10 | Lung | Primary cancer | 1,720 | Stromal | 29.2% | 0.79 | 0.47 |
| NSCLC_38242124__IMC__86_C2,11 | Lung | Primary cancer | 558 | Tumor/Malignant | 37.1% | 0.69 | 0.64 |
| NSCLC_38242124__IMC__86_C2,12 | Lung | Primary cancer | 888 | Stromal | 45.5% | 0.86 | 0.39 |
| NSCLC_38242124__IMC__86_C2,14 | Lung | Primary cancer | 1,996 | Tumor/Malignant | 28.6% | 0.95 | 0.14 |
| NSCLC_38242124__IMC__86_C2,3 | Lung | Primary cancer | 2,535 | Tumor/Malignant | 54.9% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__86_C2,4 | Lung | Primary cancer | 3,494 | Tumor/Malignant | 55.6% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__86_C2,6 | Lung | Primary cancer | 3,518 | Tumor/Malignant | 84.5% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__86_C2,9 | Lung | Primary cancer | 416 | Tumor/Malignant | 79.8% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_C3,1 | Lung | Primary cancer | 4,253 | Tumor/Malignant | 72.2% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__86_C3,11 | Lung | Primary cancer | 2,737 | Tumor/Malignant | 80.4% | 0.98 | 0.05 |
| NSCLC_38242124__IMC__86_C3,12 | Lung | Primary cancer | 2,904 | Tumor/Malignant | 51.7% | 0.97 | 0.13 |
| NSCLC_38242124__IMC__86_C3,14 | Lung | Primary cancer | 1,663 | Other | 30.4% | 0.51 | 0.87 |
| NSCLC_38242124__IMC__86_C3,3 | Lung | Primary cancer | 3,442 | Tumor/Malignant | 31.3% | 0.96 | 0.17 |
| NSCLC_38242124__IMC__86_C3,5 | Lung | Primary cancer | 3,005 | Immune | 42.4% | 0.87 | 0.34 |
| NSCLC_38242124__IMC__86_C3,6 | Lung | Primary cancer | 3,758 | Tumor/Malignant | 65.7% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__86_C3,7 | Lung | Primary cancer | 4,140 | Other | 29.7% | 0.52 | 0.83 |
| NSCLC_38242124__IMC__86_C3,9 | Lung | Primary cancer | 2,739 | Tumor/Malignant | 56.9% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__86_C4,1 | Lung | Primary cancer | 2,359 | Stromal | 35.3% | 0.48 | 0.83 |
| NSCLC_38242124__IMC__86_C4,10 | Lung | Primary cancer | 3,299 | Tumor/Malignant | 36.3% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__86_C4,11 | Lung | Primary cancer | 1,825 | Stromal | 37.3% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__86_C4,12 | Lung | Primary cancer | 2,589 | Tumor/Malignant | 72.0% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_C4,13 | Lung | Primary cancer | 1,103 | Stromal | 27.4% | 0.44 | 0.93 |
| NSCLC_38242124__IMC__86_C4,3 | Lung | Primary cancer | 1,126 | Stromal | 49.8% | 0.91 | 0.26 |
| NSCLC_38242124__IMC__86_C4,5 | Lung | Primary cancer | 2,882 | Tumor/Malignant | 78.5% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__86_C4,7 | Lung | Primary cancer | 3,469 | Immune | 30.0% | 0.43 | 0.91 |
| NSCLC_38242124__IMC__86_C4,8 | Lung | Primary cancer | 2,960 | Immune | 47.0% | 0.92 | 0.26 |
| NSCLC_38242124__IMC__86_C4,9 | Lung | Primary cancer | 1,591 | Stromal | 40.9% | 0.77 | 0.53 |
| NSCLC_38242124__IMC__86_C5,1 | Lung | Primary cancer | 3,797 | Tumor/Malignant | 66.4% | 0.95 | 0.15 |
| NSCLC_38242124__IMC__86_C5,10 | Lung | Primary cancer | 2,758 | Tumor/Malignant | 59.3% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__86_C5,4 | Lung | Primary cancer | 228 | Stromal | 57.9% | 0.64 | 0.45 |
| NSCLC_38242124__IMC__86_C5,6 | Lung | Primary cancer | 700 | Other | 29.6% | 0.32 | 0.99 |
| NSCLC_38242124__IMC__86_C5,9 | Lung | Primary cancer | 3,437 | Immune | 38.9% | 0.92 | 0.23 |
| NSCLC_38242124__IMC__86_C6,1 | Lung | Primary cancer | 3,873 | Immune | 49.6% | 0.90 | 0.27 |
| NSCLC_38242124__IMC__86_C6,10 | Lung | Primary cancer | 5,526 | Tumor/Malignant | 52.1% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__86_C6,11 | Lung | Primary cancer | 2,196 | Tumor/Malignant | 31.9% | 0.52 | 0.63 |
| NSCLC_38242124__IMC__86_C6,6 | Lung | Primary cancer | 2,518 | Tumor/Malignant | 38.0% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__86_C6,8 | Lung | Primary cancer | 2,712 | Tumor/Malignant | 51.7% | 0.96 | 0.17 |
| NSCLC_38242124__IMC__86_C7,1 | Lung | Primary cancer | 3,644 | Tumor/Malignant | 55.5% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__86_C7,14 | Lung | Primary cancer | 4,956 | Immune | 93.1% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__86_C7,4 | Lung | Primary cancer | 4,395 | Tumor/Malignant | 31.1% | 0.89 | 0.33 |
| NSCLC_38242124__IMC__86_C7,6 | Lung | Primary cancer | 4,721 | Tumor/Malignant | 59.1% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_C7,7 | Lung | Primary cancer | 412 | Tumor/Malignant | 54.4% | 0.87 | 0.33 |
| NSCLC_38242124__IMC__86_C8,1 | Lung | Primary cancer | 4,014 | Tumor/Malignant | 81.5% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_C8,14 | Lung | Primary cancer | 941 | Other | 30.7% | 0.49 | 0.83 |